Molson Coors Q2 Earnings & Sales Beat, Stock Dips on Bleak View

Molson Coors (TAP) reported Q2 2025 adjusted EPS of $2.05 and net sales of $3.2 billion, both surpassing consensus estimates, despite a 7% year-over-year volume decline largely offset by a 4.4% price/sales mix improvement. However, the stock declined 1.3% in pre-market trading as the company issued a significantly bleaker 2025 outlook, now projecting constant-currency sales to fall 3-4% and EPS to decline 7-10% year-over-year, citing macroeconomic headwinds and softer U.S. market share performance.

Analysis

Molson Coors (TAP) presented a mixed Q2 2025 financial report where headline figures surpassed analyst estimates, but underlying fundamentals and forward guidance revealed significant deterioration. While adjusted EPS rose 6.8% YoY to $2.05 and net sales of $3.2 billion beat forecasts, these results were overshadowed by a sharp 7% YoY decline in financial volumes. The company partially mitigated this volume loss with a 4.4% improvement in price and sales mix, pointing to effective premiumization and pricing strategies. However, this was not enough to prevent a 3.6% drop in gross profit and a 30-basis-point contraction in gross margin. The primary catalyst for the negative market reaction, a 1.3% pre-market share price drop, was the severe downward revision of its full-year 2025 guidance. The company now projects a 3-4% decline in constant-currency sales and a 7-10% decline in underlying EPS, a stark reversal from previous expectations of a low-single-digit EPS growth. This bleak outlook, attributed to macroeconomic pressures and softer U.S. market share, confirms the negative trend reflected in the stock's 15.2% decline over the past three months, a performance significantly worse than the industry's 7.4% drop.

Key Decisions for Investors

• Given the substantial downward revision to full-year 2025 guidance, which projects an EPS decline of 7-10%, the Q2 earnings beat should be viewed with skepticism, warranting a cautious or bearish short-term stance.
• Investors should critically assess the sustainability of the company's pricing power, as the 4.4% price/mix improvement is proving insufficient to offset the steep 7% volume decline and contracting gross margins.
• The stock's significant underperformance relative to its industry peers highlights company-specific issues, primarily the loss of U.S. market share, which should be monitored closely as a key indicator for any potential turnaround.